Related Experiment Video
Updated: Feb 7, 2026

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
Published on: May 19, 2018
Patient-Derived Stem Cell Models in SPAST HSP: Disease Modelling and Drug Discovery
Gautam Wali1, Carolyn M Sue2, Alan Mackay-Sim3
1Department of Neurogenetics, Kolling Institute of Medical Research, The University of Sydney, Sydney, NSW 2065, Australia. gautam.wali@sydney.edu.au.
Abstract:
Hereditary spastic paraplegia is an inherited, progressive paralysis of the lower limbs first described by Adolph Strümpell in 1883 with a further detailed description of the disease by Maurice Lorrain in 1888. Today, more than 100 years after the first case of HSP was described, we still do not know how mutations in HSP genes lead to degeneration of the corticospinal motor neurons. This review describes how patient-derived stem cells contribute to understanding the disease mechanism at the cellular level and use this for discovery of potential new therapeutics, focusing on SPAST mutations, the most common cause of HSP.
Related Concept Videos
Drug Discovery: Overview
Induced Pluripotent Stem Cells
Embryonic Stem Cells
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Adult Stem Cells

